In the current month, CELU has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CELU average Analyst price target in the last month is 6.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
Strong Buy
0
0
0
0
0
0
0
0
Buy
0
0
0
0
0
1
1
1
Hold
0
0
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
0
0
Sell
0
0
0
0
0
0
0
0
Total
0
0
0
0
0
1
1
1
CELU Analyst Rating for Peer Comparison
Updated: Nov 5, 2026
Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Ratings
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
Forecast
--
--
--
Actual
-0.86
0.02
0.02
Surprise
--
--
--
FAQs
What is Celularity Inc's price target?
Analysts forecast that Celularity Inc's price target is USD 6.00, with the highest forecast at USD 6.00 and the lowest forecast at USD 6.00.